Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • University of Utah • HR+ • NCI-CCC Breast Tumor Board Question • Breast Cancer, Non-metastatic
Do you utilize MammaPrint testing to determine whether or not to offer neoadjuvant chemotherapy for high-risk ER+ breast cancer?
Answer from: Medical Oncologist at Academic Institution
Yes, MammaPrint is a genomic test that can be used to identify ER+ patients who benefit from adjuvant chemotherapy. If a patient is predicted to benefit from adjuvant chemotherapy, she will also benefit to the same extent if she receives the treatment preoperatively.Preoperative administration may b...
Sign In or Register to read more
Answer from: Medical Oncologist at Community Practice
Outside of T3/T4 or N2/3 disease, high-risk ER-positive breast cancers are hard to be ascertained without doing genomic assays.We do have published data supporting the use of both MammaPrint and Oncotype performed on Core Bx to guide us on neoadjuvant endocrine therapy versus chemotherapy. Two ...
Comments
Medical Oncologist at Warren Alpert Medical School of Brown University
I agree that in high-risk patients (clinical T4, N...
I agree that in high-risk patients (clinical T4, N...
Medical Oncologist at Emory Saint Joseph's Hospital
@William M. Sikov if it ends up a high risk (T2N1,...
@William M. Sikov if it ends up a high risk (T2N1,...
Medical Oncologist at CompHealth
TC
TC
Medical Oncologist at Texas Oncology
And what about recent data showing no benefit to c...
And what about recent data showing no benefit to c...
Answer from: Medical Oncologist at Community Practice
It’s reasonable to use a genomic assay to determine whether patients with localized (T1-3N0-1) HR+HER2- breast cancer would derive benefit from neoadjuvant chemotherapy. MammaPrint is a prognostic and somewhat predictive test that may have utility in these cases. Data suggests it is best used ...